- Home
- CRML vs KROS Comparison
CRML vs KROS Comparison
Compare CRML & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRML
- KROS
- Stock Information
- Founded
- CRML N/A
- KROS 2015
- Country
- CRML United States
- KROS United States
- Employees
- CRML N/A
- KROS N/A
- Industry
- CRML
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CRML
- KROS Health Care
- Exchange
- CRML NYSE
- KROS Nasdaq
- Market Cap
- CRML 604.3M
- KROS 589.8M
- IPO Year
- CRML N/A
- KROS 2020
- Fundamental
- Price
- CRML $8.80
- KROS $12.51
- Analyst Decision
- CRML
- KROS Buy
- Analyst Count
- CRML 0
- KROS 11
- Target Price
- CRML N/A
- KROS $68.83
- AVG Volume (30 Days)
- CRML 48.5K
- KROS 2.1M
- Earning Date
- CRML 02-01-2025
- KROS 02-26-2025
- Dividend Yield
- CRML N/A
- KROS N/A
- EPS Growth
- CRML N/A
- KROS N/A
- EPS
- CRML N/A
- KROS N/A
- Revenue
- CRML $117,660.00
- KROS $651,000.00
- Revenue This Year
- CRML N/A
- KROS $224.66
- Revenue Next Year
- CRML N/A
- KROS N/A
- P/E Ratio
- CRML N/A
- KROS N/A
- Revenue Growth
- CRML 5.79
- KROS 8037.50
- 52 Week Low
- CRML $5.32
- KROS $12.35
- 52 Week High
- CRML $22.50
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- CRML 71.67
- KROS 20.37
- Support Level
- CRML $6.61
- KROS $12.35
- Resistance Level
- CRML $9.89
- KROS $16.49
- Average True Range (ATR)
- CRML 0.64
- KROS 0.84
- MACD
- CRML 0.21
- KROS 1.01
- Stochastic Oscillator
- CRML 70.29
- KROS 3.69
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.